Consolidated net profit for the March quarter rose to ₹15.9 crore from ₹1.2 crore in the year-ago period. The profitability was also aided by a one-time gain of ₹2.9 crore from the divestment of a stake in Texas Lifescience Pvt. Ltd.
During the quarter, the company completed the divestment of 43.81% equity stake in Texas Lifescience Pvt. Ltd., following which the entity ceased to be a subsidiary from March 27, 2026.
Revenue increased by 22% year-on-year to ₹100 crore from ₹82 crore a year ago.
Earnings before Interest, Tax, Depreciation, Amortisation (EBITDA) jumped 78% to ₹34.2 crore from ₹19.2 crore, while EBITDA margin expanded to 34.2% from 23.4% a year ago.
Hester Bio In FY26
For FY26, consolidated revenue rose to ₹332.6 crore from ₹311.1 crore in FY25, while profit after tax nearly doubled to ₹57.5 crore from ₹28.8 crore a year ago.
The company’s poultry healthcare segment remained the largest contributor to revenue, adding ₹206 crore, up from ₹167 crore in FY25. Animal healthcare revenue, however, declined to ₹126.6 crore from ₹143.6 crore a year ago.
Hester Biosciences’ board has recommended a dividend of ₹11 per equity share for FY26, subject to shareholder approval at the upcoming annual general meeting.
Shares of Hester Biosciences are trading 13% higher after the results announcement at ₹1,962. The stock has extended its gains for the last one month to 36%, as a result of which, the stock has also turned positive on a year-to-date basis.
